These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 33152277

  • 1. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
    Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Vonk E, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Van Limbergen EF, Engelen A, De Brouwer P, Struikmans H, Bartelink H, European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups.
    Lancet Oncol; 2020 Dec; 21(12):1602-1610. PubMed ID: 33152277
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
    Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L, European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups.
    Lancet Oncol; 2015 Jan; 16(1):47-56. PubMed ID: 25500422
    [Abstract] [Full Text] [Related]

  • 5. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators.
    Lancet Oncol; 2015 Mar; 16(3):266-73. PubMed ID: 25637340
    [Abstract] [Full Text] [Related]

  • 6. Which target volume should be considered when irradiating the regional nodes in breast cancer? Results of a network-meta-analysis.
    Haussmann J, Budach W, Tamaskovics B, Bölke E, Corradini S, Djiepmo-Njanang FJ, Kammers K, Matuschek C.
    Radiat Oncol; 2019 Jun 11; 14(1):102. PubMed ID: 31186015
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials.
    Budach W, Kammers K, Boelke E, Matuschek C.
    Radiat Oncol; 2013 Nov 14; 8():267. PubMed ID: 24225206
    [Abstract] [Full Text] [Related]

  • 8. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ.
    Lancet Oncol; 2014 Nov 14; 15(12):1303-10. PubMed ID: 25439688
    [Abstract] [Full Text] [Related]

  • 9. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
    Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Uter W, Strnad V, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO).
    Lancet Oncol; 2017 Feb 14; 18(2):259-268. PubMed ID: 28094198
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
    Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, EORTC Melanoma Group.
    Lancet Oncol; 2021 May 14; 22(5):643-654. PubMed ID: 33857412
    [Abstract] [Full Text] [Related]

  • 11. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial.
    Kaidar-Person O, Fortpied C, Hol S, Weltens C, Kirkove C, Budach V, Peignaux-Casasnovas K, van der Leij F, Vonk E, Valli M, Weidner N, Guckenberger M, Koiter E, Fourquet A, Bartelink H, Struikmans H, Poortmans P, EORTC Radiation Oncology and Breast Cancer Groups.
    Radiother Oncol; 2022 Jul 14; 172():99-110. PubMed ID: 35568284
    [Abstract] [Full Text] [Related]

  • 12. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
    Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS, MRC SUPREMO trial UK investigators.
    Lancet Oncol; 2018 Nov 14; 19(11):1516-1529. PubMed ID: 30337220
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update.
    Budach W, Bölke E, Kammers K, Gerber PA, Nestle-Krämling C, Matuschek C.
    Radiat Oncol; 2015 Dec 21; 10():258. PubMed ID: 26691175
    [Abstract] [Full Text] [Related]

  • 14. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A, International Breast Cancer Study Group Trial 23-01.
    Lancet Oncol; 2018 Oct 21; 19(10):1385-1393. PubMed ID: 30196031
    [Abstract] [Full Text] [Related]

  • 15. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT.
    Lancet Oncol; 2021 Apr 21; 22(4):476-488. PubMed ID: 33721561
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
    Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.
    Lancet Oncol; 2012 Jun 21; 13(6):589-97. PubMed ID: 22575589
    [Abstract] [Full Text] [Related]

  • 17. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L, EORTC Radiation Oncology Group.
    Lancet Oncol; 2014 Feb 21; 15(2):184-90. PubMed ID: 24440473
    [Abstract] [Full Text] [Related]

  • 18. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer.
    Fowble B, Hanlon A, Freedman G, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Torosian M, Goldstein L.
    Int J Radiat Oncol Biol Phys; 2000 Jul 01; 47(4):883-94. PubMed ID: 10863056
    [Abstract] [Full Text] [Related]

  • 19. Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
    Orecchia R, Veronesi U, Maisonneuve P, Galimberti VE, Lazzari R, Veronesi P, Jereczek-Fossa BA, Cattani F, Sangalli C, Luini A, Caldarella P, Venturino M, Sances D, Zurrida S, Viale G, Leonardi MC, Intra M.
    Lancet Oncol; 2021 May 01; 22(5):597-608. PubMed ID: 33845035
    [Abstract] [Full Text] [Related]

  • 20. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients.
    Courdi A, Chamorey E, Ferrero JM, Hannoun-Lévi JM.
    Radiother Oncol; 2013 Aug 01; 108(2):259-65. PubMed ID: 23891092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.